Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Kite Pharma Inc (NASDAQ:KITE)

76.84
Delayed Data
As of Mar 24
 +2.34 / +3.14%
Today’s Change
39.82
Today|||52-Week Range
88.58
+71.36%
Year-to-Date
Pfizer's Immunotherapy for Skin Cancer Gets FDA Approval
Mar 24 / Zacks.com - Paid Partner Content
3 Reasons Why Gilead Sciences Will Buy Incyte -- and 1 Reason Why It Won't
Mar 15 / MotleyFool.com - Paid Partner Content
Regenxbio Leads Biotech Movers Ahead of Market's Open
Mar 22 / TheStreet.com - Paid Partner Content
Top Stocks That Are Already Crushing the Market in 2017
Mar 13 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close74.50
Today’s open74.65
Day’s range74.58 - 77.75
Volume1,063,363
Average volume (3 months)1,353,100
Market cap$4.1B
Dividend yield--
Data as of 3:59pm ET, 03/24/2017

Growth & Valuation

Earnings growth (last year)-134.33%
Earnings growth (this year)-46.38%
Earnings growth (next 5 years)--
Revenue growth (last year)+28.46%
P/E ratioNM
Price/Sales98.98
Price/Book8.72

Competitors

 Today’s
change
Today’s
% change
TECHBio-Techne Corp+0.32+0.31%
NBIXNeurocrine Bioscienc...+0.48+1.16%
BLUEbluebird bio Inc+1.15+1.32%
NKTRNektar Therapeutics-0.11-0.49%
Data as of 4:14pm ET, 03/24/2017

Financials

Next reporting dateMay 19, 2017
EPS forecast (this quarter)-$1.65
Annual revenue (last year)$22.2M
Annual profit (last year)-$267.1M
Net profit margin-1,204.65%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Arie S. Belldegrun
Chief Operating Officer
Cynthia M. Butitta
Corporate headquarters
Santa Monica, California

Forecasts


Search for Jobs